Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for Izicopan (C5aR Inhibitor) in IgA Nephropathy. The expected timing is based on the latest available company guidance and may change.
05/06/26:- Open-label IgA nephropathy studies expected to begin generating clinical data in 2027. 08/06/26:- IgAN open-label proof-of-concept data remain expected in 2027.
Verification
Confirm timing and program details against the company announcement or filing.